MAP2K7 and melanoma: It has been reported that ceritinib enhances the efficacy of trametinib, a MEK inhibitor, in BRAF/NRAS‐wt melanoma cell lines [38], which makes it plausible that ceritinib would not have any effect in BRAF‐mutated cells.